1. Home
  2. IHS vs SUPN Comparison

IHS vs SUPN Comparison

Compare IHS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IHS Holding Limited

IHS

IHS Holding Limited

HOLD

Current Price

$8.32

Market Cap

2.8B

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$46.34

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHS
SUPN
Founded
2001
2005
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.0B
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
IHS
SUPN
Price
$8.32
$46.34
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$8.29
$61.60
AVG Volume (30 Days)
1.0M
678.4K
Earning Date
05-19-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$392,755,000.00
Revenue This Year
$17.26
$22.70
Revenue Next Year
$7.87
$19.14
P/E Ratio
$5.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.45
$31.16
52 Week High
$8.95
$59.68

Technical Indicators

Market Signals
Indicator
IHS
SUPN
Relative Strength Index (RSI) 56.95 37.60
Support Level $8.14 $43.67
Resistance Level $8.34 $46.89
Average True Range (ATR) 0.05 1.69
MACD 0.01 -0.34
Stochastic Oscillator 51.28 5.43

Price Performance

Historical Comparison
IHS
SUPN

About IHS IHS Holding Limited

IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: